RNA Interference in the Post-Genomic Era: Markets and Technologies

Abstract

• The global market for RNA interference (RNAi) was $145.2 million in 2007 and is expected to reach $174.5 million by the end of 2008. It should reach $3.6 billion by 2013, a compound annual growth rate (CAGR) of 83.4%.
• RNAi is already an established enabling biotechnology product platform and its future use in diagnostics and therapeutics may rival such products as recombinant proteins or monoclonal antibodies.
• The growth rate of the research and development tools market segment is forecast to be a robust 19.5% per year during the study period to reach $424.5 million in 2013.

• Descriptions of various RNA interference (RNAi) technologies including research and development tools, diagnostics, therapeutics and agricultural applications.
• The current global market status of the RNAi industry, with trends and forecasts for growth over the next 5 years
• Analysis of the RNAi industry on a worldwide basis, both from a market and application perspective
• Discussion of state-of-the-art RNAi technologies and their future commercial potential
• Profiles of the main companies in the RNAi field.

BCC presents an analysis of each of the key market segments that will be commercially important during the next 5 years: research tools, diagnostics, agriculture and therapeutics. Based on our analysis, we look at the potential applications of RNA interference in each of the major market segments, and forecast sales revenues for 2008 through 2013.

For research tools and drug discovery and development, the study presents a forecast from 2008 through 2013 for each of the important products and associated technologies. For diagnostics and therapeutics, we forecast from 2008 through 2013 the RNAi-based diagnostics and drugs that are expected to come onto the market by type. For agriculture, we forecast the main product types to come onto the market from 2008 through 2013.